Precede Biosciences

🔬 Exciting progress from our portfolio company, Precede Biosciences! At SABCS 2024, Precede presented their novel ER Transcriptional Dependency Index (PERDI), a blood-based test designed to enhance the use of endocrine therapy in ER+ metastatic #BreastCancer.     This innovative approach addresses critical unmet needs in treatment decision-making, with the potential to identify patients who might benefit from monotherapy with emerging oral selective estrogen receptor degraders (SERDs) and antibody-drug conjugates (ADCs).    Learn more about Precede’s impactful work here: https://lnkd.in/dNjPqyYK    #PartnerNews 

Thank you to everyone who stopped by our #SABCS24 poster spotlight presentation with Precede Biosciences' Jonathan Beagan today. We love sharing our science and appreciate the interest in scientific exchange. #LiquidBiopsy #BreastCancer #DrugDevelopment

Precede Biosciences presents a novel ER transcriptional dependency index at #SABCS24 designed to further inform use of endocrine therapy from a simple blood test. View press release: https://bit.ly/41p9HOW #BreastCancer #LiquidBiopsy #DrugDevelopment #SERDs #ADCs

Precede Biosciences’ COO Jennifer Fortune sat down with Tom Froggatt of Singular: Building Brilliant Biotechs to discuss her career journey, words of wisdom for new PhDs, and the game-changing potential of epigenomics in precision medicine. Check out the interview: https://lnkd.in/gbEWdPXy.

Team Precede Biosciences is onsite and ready to mingle at #SABCS24: Say hello to Jonathan Beagan, Corrie Painter, Aparna Gorthi, and J.Carl Barrett. #LiquidBiopsy #DreamTeam

Check out the latest interview with Precede Biosciences' CSO J.Carl Barrett and journalist Caroline Hopkins Legaspi in Precision Medicine Online. (subscription required) #PrecisionMedicine #DrugDevelopment #PSMA #ProstateCancer

This year’s Life Science nominees at the #NEVYs24 are breaking boundaries and changing lives. From early-stage pioneers to industry powerhouses, these companies are paving the way for the future of the life science industry. Here’s a closer look at the awards up for grabs as these contestants prepare to battle it out next week at #NEVYsSurvivor! 🏆 Emerging Life Science Company of the Year 💡 – Visionary early-stage companies with groundbreaking technologies and ambitious teams who are rewriting the rules: Precede Biosciences  ARTBIO  Diagonal Therapeutics  Clasp Therapeutics  Nvelop Therapeutics Powerhouse Life Science Company of the Year 💪 – Resilient companies that have made waves with IPOs, M&As, or transformative deals, amplifying their impact across the ecosystem: Cerevel Therapeutics  Mariana Oncology  Morphic Therapeutic Neumora Learn more about the rest of the nominees here! https://lnkd.in/e7f7mfDZ #NEVCA #Innovation

Check out the latest article from Hannah Clarke in Urology Times on data in mCRPC from our collaboration with Dr. Jacob Berchuck of Winship Cancer Institute of Emory University at #ISLB24 and #AACRLBx24. View article: https://lnkd.in/gd5RfkSz #ProstateCancer #PSMA #DrugDevelopment #LiquidBiopsy #Epigenomics

#SABCS24 abstracts are out! Join Jonathan Beagan and our team from Precede Biosciences for a poster spotlight session highlighting the latest data for our #LiquidBiopsy platform in stratifying patients with ER+ breast cancer for therapy selection. View abstracts: https://bit.ly/3AY96c6 #BreastCancer #PrecisionMedicine #DrugDevelopment #SERDs

Precede Biosciences Unveils AACR LBx 2024 Data on Blood Test for Tumor PSMA and Lutetium-PSMA Response in mCRPC Rehan Verjee Jacob Berchuck https://lnkd.in/eB2VQh37 #AACR #AACRLBx2024 #Cancer #LutetiumPSMA #mCRPC #OncoDaily #Oncology #PrecedeBiosciences #ProstateCancer #PSATesting #PSMA #PETScan #Medicine #Health